ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,728.80
0.41%
US Tech 100
19,516.40
0.10%
Dow Jones
42,052.19
0.69%
Brent Oil
74.96
1.19%
Bitcoin
68,762.61
0.03%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) News

ATHE

Alterity Therapeutics (ATHE)

Alterity Therapeutics Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATHE
DateTimeSourceHeadlineSymbolCompany
10/31/20247:35AMGlobeNewswire Inc.Appendix 4C – Q1 FY25 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
10/14/20247:35AMGlobeNewswire Inc.Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024NASDAQ:ATHEAlterity Therapeutics Limited
10/11/20247:35AMGlobeNewswire Inc.Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience MeetingNASDAQ:ATHEAlterity Therapeutics Limited
10/02/20247:35AMGlobeNewswire Inc.Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®NASDAQ:ATHEAlterity Therapeutics Limited
09/30/20247:35AMGlobeNewswire Inc.Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerNASDAQ:ATHEAlterity Therapeutics Limited
09/23/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
09/23/20247:35AMGlobeNewswire Inc.Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®NASDAQ:ATHEAlterity Therapeutics Limited
08/29/20246:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
07/31/20247:35AMGlobeNewswire Inc.Appendix 4C – Q4 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
07/31/20246:23AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
07/24/20247:35AMGlobeNewswire Inc.Alterity Therapeutics to Present at MST Financial WebinarNASDAQ:ATHEAlterity Therapeutics Limited
07/17/20247:35AMGlobeNewswire Inc.Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
07/17/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
06/13/20248:28AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
06/12/20247:22PMGlobeNewswire Inc.Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ WebinarNASDAQ:ATHEAlterity Therapeutics Limited
05/29/20247:21PMGlobeNewswire Inc.Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyNASDAQ:ATHEAlterity Therapeutics Limited
05/08/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewNASDAQ:ATHEAlterity Therapeutics Limited
04/30/20247:25AMGlobeNewswire Inc.Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
04/29/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaNASDAQ:ATHEAlterity Therapeutics Limited
04/17/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
04/10/20247:25AMGlobeNewswire Inc.Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024NASDAQ:ATHEAlterity Therapeutics Limited
03/26/202410:25AMGlobeNewswire Inc.Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
02/20/202410:25AMGlobeNewswire Inc.Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
02/15/20245:29PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
02/15/20245:28PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATHEAlterity Therapeutics Limited
02/06/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewNASDAQ:ATHEAlterity Therapeutics Limited
01/31/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
01/29/20247:24AMGlobeNewswire Inc.Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekNASDAQ:ATHEAlterity Therapeutics Limited
01/22/20247:25AMGlobeNewswire Inc.Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesNASDAQ:ATHEAlterity Therapeutics Limited
01/22/20246:12AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
 Showing the most relevant articles for your search:NASDAQ:ATHE

Your Recent History

NASDAQ
ILLR
Triller
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
LWLG
Lightwave Logic
USOTC
HIRU
Hiru (PK)
NASDAQ
NB
NioCorp Developments
NASDAQ
TSLA
Tesla
USOTC
PSRU
Valiant Eagle (PK)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
AMRN
Amarin
USOTC
FNMA
Fannie Mae (QB)
USOTC
GNCP
GNCC Capital (CE)
USOTC
RDAR
Raadr (PK)
USOTC
RNVA
Rennova Health (CE)
USOTC
AFFU
Affluence (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved